Prostate Cell News Volume 6.21 | Jun 12 2015

Development of Novel Radio-Chemotherapy Approaches Targeting Prostate Tumor Progenitor Cells Using Nanohybrids
Investigators describe the synthesis of biocompatible, catechin-loaded and gelatin-conjugated carbon nanotubes with anticancer properties and demonstrate their potential for the eradication of prostate cancer stem cells in combination with X-ray irradiation. [Int J Cancer] Abstract

Capsaicin Reduces the Metastatic Burden in the Transgenic Adenocarcinoma of the Mouse Prostate Model
Scientists investigated the chemopreventive potential of capsaicin on prostate cancer using the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. The TRAMP is a murine model that resembles the progression of human disease. [Prostate] Abstract

Androgens Enhance the Glycolytic Metabolism and Lactate Export in Prostate Cancer Cells by Modulating the Expression of GLUT1, GLUT3, PFK, LDH and MCT4 Genes
Researchers investigated the role of androgens in controlling the glycolytic metabolism and lactate efflux in prostate cancer cells. Androgen-responsive LNCaP cells were treated with 5α-dihydrotestosterone for 12-48 hours, and their glycolytic metabolism, lactate production and viability were analyzed. [J Cancer Res Clin Oncol] Abstract

Gabarapl1 Mediates Androgen-Regulated Autophagy in Prostate Cancer
Scientists found that GABA(Archive) receptor-associated protein like 1 (Gabarapl1), a ubiquitin-like modifier, participates in the regulation of autophagy. Gabarapl1 is transcriptionally regulated by androgen receptor and has a repressive role in autophagy. [Tumor Biol] Abstract

The Stress Hormone Norepinephrine Increases Migration of Prostate Cancer Cells In Vitro and In Vivo
Investigators examined norepinephrine’s possible role in metastasis formation and development in vitro and in vivo. Treatments with norepinephrine in mice xenografted with human DU145 prostate cancer cells increased the metastatic potential of these cells. [Int J Oncol] Abstract

CLINICAL RESEARCH

A Randomized, Double-Blind Study Comparing the Addition of Bicalutamide with or without Dutasteride to GnRH Analog Therapy in Men with Non-Metastatic Castrate-Resistant Prostate Cancer
Researchers prospectively evaluated dutasteride plus bicalutamide in men with asymptomatic, non-metastatic castration-resistant prostate cancer with rising prostate-specific antigen. [Eur J Cancer] Abstract

Categorical versus Continuous Circulating Tumor Cell Enumeration as Early Surrogate Marker for Therapy Response and Prognosis during Docetaxel Therapy in Metastatic Prostate Cancer Patients
Investigators prospectively assessed categorical and continuous circulating tumor cell-counts for their utility in early prediction of radiographic response, progression-free and overall survival in metastatic castration-resistant prostate cancer patients treated with docetaxel. [BMC Cancer] Full Article

Efficacy of Treatment with a GnRH Antagonist in Prostate Cancer Patients Previously Treated with a GnRH Agonist
Researchers retrospectively examined 18 patients with prostate cancer who received androgen-deprivation therapy and who were treated with a GnRH antagonist (degarelix) after they showed an elevated PSA while on GnRH agonist therapy. [Cancer Chemother Pharmacol] Abstract

Anticancer Properties of Carotenoids in Prostate Cancer
Clear clinical evidence supporting the use of carotenoids in prevention or treatment of prostate cancer is not available, due to the limited number of published randomized clinical trials, and the varying protocols used in the existing studies. The authors discussed the potential impact of carotenoids on prostate cancer by giving an overview of the molecular mechanisms and in vitro/in vivo effects. [Histol Histopathol] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Cancer Research at Rhode Island Hospital Gets $5.8 Million Boost from the National Institutes of Health
The National Institutes of Health has awarded Rhode Island Hospital $5.8 million to support the hospital’s cancer research program. [Rhode Island Hospital] Press Release

STEMCELL Technologies Named Company of the Year by BIOTECanada
STEMCELL Technologies Inc. will be presented with the Biotech Company of the Year award by BIOTECanada at this year’s BIO International Convention in Philadelphia. [BIOTECanada] Press Release

From our sponsor:
Webinar: Neural Stem Cell Culture Systems – Neurosphere vs. Adherent Monolayer Culture. Watch now.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Fellows – Molecular Mechanisms of Prostate Cancer Progression and Therapeutic Resistance (Tulane University School of Medicine)

Postdoctoral Fellowship – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic Lerner Research Institute)

Research Scientists – Tissue Biorepository and Data Resource for Prostate Cancer (NYU Langone Medical Center)

Research Assistant Professor or Instructor – Prostate Cancer (Thomas Jefferson University)

Postdoctoral Positions – Cancer, Stem Cell, and Developmental Biology (Columbia University Medical Center)

Senior Postdoctoral Position – Prostate Cancer (Institut Paoli Calmettes)

Postdoctoral Positions – Molecular Cancer Biology (University of Pennsylvania)

Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

Postdoctoral Research Fellow/Instructor – Prostate/Breast Cancer (Baylor College of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.